Posts by Mourabit Halima

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer, offers an innovative head-to-head comparison between a carboplatin-free THP regimen and the traditional carboplatin-containing TCbHP regimen. The findings revealed that the THP regimen was non-inferior to TCbHP in terms of pathological complete response (pCR), with a significantly better toxicity profile. This important discovery not only provides a new therapeutic option for patients with HER2-positive breast cancer but also reflects a patient-centered approach to treatment—marking a shift toward more precise and individualized care. Following the presentation, Oncology Frontier interviewed Professor Wang to discuss the study’s background, significance, and what the future holds for HER2-positive breast cancer treatment.

Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.

The therapeutic landscape in oncology is undergoing a profound shift with the rise of genome engineering technologies such as CRISPR/Cas9, base editing, and prime editing. These tools are enabling the…